Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

[1]  Andrew J S Coats,et al.  Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. , 2003, Journal of cardiac failure.

[2]  S. Anker,et al.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.

[3]  K. Witte,et al.  Nutritional abnormalities contributing to cachexia in chronic illness. , 2002, International journal of cardiology.

[4]  S. Anker,et al.  Cytokines, apoptosis and cachexia: the potential for TNF antagonism. , 2002, International journal of cardiology.

[5]  S. Anker,et al.  The syndrome of cardiac cachexia. , 2002, International journal of cardiology.

[6]  P. Poole‐Wilson,et al.  The cardiac component of cardiac cachexia. , 2002, American heart journal.

[7]  R. Hetzer,et al.  Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. , 2001, European heart journal.

[8]  G. Fonarow,et al.  The relationship between obesity and mortality in patients with heart failure. , 2001, Journal of the American College of Cardiology.

[9]  P. Poole‐Wilson,et al.  Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. , 2001, Journal of the American College of Cardiology.

[10]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[11]  S. Anker,et al.  Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. , 2001, American heart journal.

[12]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[13]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[14]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[15]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[16]  P. Ponikowski,et al.  Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. , 1999, European heart journal.

[17]  H. Drexler,et al.  Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. , 1998, European heart journal.

[18]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[19]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[20]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[21]  P. Poole‐Wilson,et al.  The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. , 1997, European heart journal.

[22]  J. Alexander,et al.  EFFECTS OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL ON BACTERIAL TRANSLOCATION AFTER THERMAL INJURY AND BACTERIAL CHALLENGE , 1996, Shock.

[23]  M. Fisher,et al.  Increased Resting Metabolic Rate in Patients with Congestive Heart Failure , 1994, Annals of Internal Medicine.

[24]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[25]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[28]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[29]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.